Advanced Bladder Cancer Treatment Strategies: A Survey

www.surveyx.cn

Abstract

This survey paper addresses the multifaceted challenges of advanced bladder cancer, emphasizing the integration of cutting-edge treatment strategies such as antibody-drug conjugates (ADCs), immunotherapy, and targeted therapy. These approaches are pivotal in managing urothelial carcinoma, the most prevalent bladder cancer subtype. The paper highlights the significance of molecular profiling and variant histology in personalizing therapies, a critical aspect in the era of precision oncology. Despite advancements, challenges such as immune evasion, treatment resistance, and the tumor microenvironment persist, necessitating innovative solutions. The integration of multimodal data is underscored as a transformative approach, enhancing biomarker discovery and treatment precision. The survey also discusses the role of technological innovations, including machine learning and advanced imaging, in refining therapeutic strategies. Furthermore, the paper explores the potential of combination therapies and novel trial designs in improving patient outcomes. The importance of social awareness and surgical quality in cancer management is also emphasized. As research continues to evolve, these advancements promise to redefine treatment paradigms, offering hope for improved survival and quality of life for patients with advanced bladder cancer. Ongoing commitment to research and innovation is crucial for overcoming the complexities of this aggressive disease and advancing the frontier of oncology.

1 Introduction

1.1 Significance of Advanced Bladder Cancer in Oncology

Advanced bladder cancer poses a significant challenge in oncology, characterized by high prevalence and mortality rates, particularly among older adults. The complexity of this malignancy is exacerbated by its diverse molecular subtypes and variant histology, complicating diagnosis and treatment and necessitating innovative therapeutic strategies. Regulated cell death (RCD) plays a crucial role in cancer progression and treatment resistance, underscoring the need for novel approaches to combat this disease [1].

The integration of engineering and physical sciences into oncology presents promising opportunities to address these challenges, potentially leading to breakthroughs in treatment methodologies [2]. Despite advancements in immunotherapy and targeted therapies, immune evasion and treatment resistance remain significant barriers, highlighting the urgent need for personalized medicine that tailors treatments to individual genetic profiles.

Furthermore, the global cancer burden, as a leading cause of death, emphasizes the necessity for effective prevention, early detection, and treatment strategies to improve patient outcomes [3]. Advanced bladder cancer serves as a focal point for ongoing research aimed at overcoming these multifaceted challenges and enhancing therapeutic efficacy [4]. Innovative treatment paradigms are essential to address current limitations and improve the quality of life and survival rates for patients with this aggressive disease.



Figure 1: chapter structure

1.2 Emergence of Cutting-Edge Treatment Strategies

The treatment landscape for advanced bladder cancer is transforming, driven by innovative strategies designed to overcome the limitations of conventional therapies and improve patient outcomes. Precision oncology is central to this evolution, focusing on identifying specific molecular targets and signaling pathways to tailor therapies to individual patient profiles, thereby enhancing treatment efficacy [5]. This approach is bolstered by the integration of multimodal data, which provides a comprehensive understanding of cancer biology and therapeutic responses [3].

Immunotherapy has emerged as a cornerstone in the treatment of advanced bladder cancer, particularly with immune checkpoint inhibitors (ICIs) demonstrating promise in clinical trials for metastatic urothelial carcinoma. These therapies are being explored in adjuvant and neoadjuvant settings, with the identification of predictive biomarkers being crucial for optimizing their clinical application [6]. Research is ongoing to discover novel pathways and molecular targets to counteract tumor-induced immune tolerance and resistance, thereby expanding the therapeutic potential of these agents [7].

AI-generated, for reference only.

Combining immunotherapy with other modalities, such as chemotherapy and nanomedicine, represents a promising strategy to enhance therapeutic efficacy, leveraging the synergistic effects of different treatments [8]. Additionally, advancements in machine learning for predicting molecular and genomic properties from histopathological images provide a cost-effective method for screening and guiding treatment decisions, further advancing precision oncology [9].

Exploring regulated cell death pathways as therapeutic targets highlights the dynamic nature of cancer treatment research, reflecting the continuous evolution of strategies to combat advanced bladder cancer. Innovative approaches in precision oncology, including the integration of multimodal data and advanced molecular diagnostics, are set to transform cancer care standards and significantly improve survival rates. By focusing on tumor genetic profiling and the unique molecular alterations driving individual cancer cases, these strategies aim to offer personalized treatment options that address tumor heterogeneity and varied patient responses to existing therapies [10, 11].

1.3 Structure of the Survey

This survey is structured to provide a comprehensive examination of advanced bladder cancer treatment strategies, emphasizing recent developments in genomic sequencing, immune checkpoint inhibitors, and non-invasive diagnostic methods, while discussing their clinical implications and potential for improved patient outcomes based on the molecular characteristics of various bladder cancer subtypes [12, 5]. The introduction highlights the significance of advanced bladder cancer in oncology and the urgent need for innovative treatment strategies.

Subsequent sections delve into the background of advanced bladder cancer, defining the condition, discussing its prevalence, and examining treatment challenges. The core sections focus on three pivotal treatment modalities: antibody-drug conjugates, immunotherapy, and targeted therapy. Each section provides an in-depth analysis, beginning with fundamental mechanisms and advancing to clinical applications and future research directions. The antibody-drug conjugates section covers mechanisms of action, recent advancements, clinical efficacy, and associated challenges. The immunotherapy section investigates mechanisms, effectiveness, and innovative approaches within this therapeutic domain, while the targeted therapy section emphasizes molecular target identification, personalized strategies, and dosing optimization.

Additionally, a section on oncology research and future directions reviews ongoing research efforts and emerging trends, crucial for understanding the integration of data modalities, innovative trial designs, and technological innovations shaping future treatment paradigms. The survey concludes with a summary of key points and a discussion on the potential impact of these advancements on patient outcomes.

Throughout the survey, the dynamic resource management system is highlighted as a primary innovation, enabling seamless transitions between processing modes based on real-time data analysis [9]. This approach enhances the adaptability and precision of treatment strategies, reflecting the survey's commitment to presenting a forward-thinking perspective on advanced bladder cancer management.The following sections are organized as shown in Figure 1.

2 Background

2.1 Definition and Stages of Advanced Bladder Cancer

Bladder cancer is a common malignancy, particularly affecting older adults, and is associated with significant morbidity and mortality [13]. Its heterogeneity in treatment responses necessitates genetic profiling for personalized therapeutic strategies [11]. Advanced bladder cancer progresses beyond superficial layers and is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), with MIBC representing a more aggressive stage [5].

Research focuses on genetic alterations, molecular subtypes, tumor microenvironment interactions, and therapeutic advancements [5]. Staging, ranging from Ta (non-invasive papillary carcinoma) to T4 (invasion of adjacent organs), is crucial for treatment planning, assessing tumor invasion depth, nodal involvement, and metastasis presence, with each stage having distinct prognostic implications.

The treatment framework integrates prevention, diagnosis, treatment, and ongoing research, stratified by cancer type, treatment modality, and patient demographics [3]. This structured approach aims to enhance personalized management of advanced bladder cancer, improving patient outcomes through precision oncology and targeted interventions.

2.2 Prevalence and Impact of Urothelial Carcinoma

Urothelial carcinoma, the predominant form of bladder cancer, accounts for approximately 90% of cases and originates from the urothelial cells lining the bladder. Its prevalence is higher in industrialized nations, with significant demographic variations [13]. Risk factors include smoking, occupational carcinogen exposure, and genetic predispositions, contributing to its high morbidity and mortality rates.

The disease often presents at advanced stages, especially in patients ineligible for cisplatin-based therapies, necessitating alternative treatments [14]. Immune checkpoint inhibitors have shown promise for metastatic urothelial carcinoma, though variable response rates and the need for predictive biomarkers complicate management.

The economic and social burden of urothelial carcinoma is substantial, requiring extensive medical resources for diagnosis, treatment, and surveillance. In 2018, bladder cancer affected over 549,000 individuals globally, resulting in nearly 200,000 deaths, underscoring the urgent need for effective management strategies. Rising incidence rates, influenced by environmental and occupational carcinogen exposures, highlight the importance of increased awareness and resource allocation to mitigate its clinical and societal impacts [13, 15]. Ongoing research into molecular underpinnings and targeted therapies holds promise for improving outcomes and reducing the impact of urothelial carcinoma.

2.3 Challenges in Treating Advanced Bladder Cancer

Treating advanced bladder cancer is challenging due to the disease's complexity and limitations of current therapies. Predicting the synergistic and antagonistic effects of combination therapies on tumor and immune cell dynamics complicates treatment optimization [16]. Additionally, the fluctuating nature of drug delivery to tumors further complicates effective treatment outcomes [17].

Despite advancements, long-term survival rates for advanced bladder cancer have stagnated, revealing variability in treatment effectiveness and inadequacies in current early detection tools [15]. The complexity of cancer biology poses additional hurdles in optimizing drug combinations to maximize efficacy while minimizing adverse effects [8], often relying on benchmarks that may not hold true in clinical trials [18].

Diagnostic challenges are critical, as current neural network approaches may lack confidence levels for mutation calls, potentially leading to incorrect treatment decisions [19]. The tumor microenvironment (TME) presents barriers to effective treatment, with factors such as hypoxia, low pH, and high interstitial fluid pressure impeding immune cell infiltration and efficacy [6].

Economic and social factors further complicate management, with high treatment costs, drug resistance, and disparities in access to care hindering effective management [3]. Addressing these challenges necessitates developing sophisticated models and therapeutic approaches that accommodate the complexities of advanced bladder cancer, including improved diagnostics, personalized treatments, and overcoming TME barriers to enhance treatment efficacy and patient outcomes.

2.4 Role of Molecular Subtypes and Variant Histology

The progression and treatment of advanced bladder cancer are significantly influenced by its molecular subtypes and variant histology, highlighting the disease's biological diversity. Bladder cancer is categorized into non-muscle-invasive and muscle-invasive tumors, each displaying unique pathological features and molecular profiles [15]. Precise molecular profiling is essential to tailor therapeutic strategies, as different subtypes may respond variably to treatments.

Urothelial carcinoma, the most common histological type, presents challenges in accurate grading and staging due to its complex histological variants, including micropapillary and plasmacytoid variants, each associated with distinct molecular classifications such as luminal and basal subtypes [15]. These molecular distinctions are crucial for determining clinical outcomes and informing management strategies, as they influence cancer behavior and treatment responses.

AI-generated, for reference only.

Recent advancements in modeling and prediction techniques have enhanced understanding of bladder cancer's molecular landscape. Integrating mathematical models to study intra-tumor heterogeneity (ITH) reveals that diverse sub-populations within a tumor, expressing different antigens, significantly impact immune response efficacy against solid tumors [20]. This heterogeneity complicates treatment, as varying antigen expression can lead to differential immune recognition.

Innovative data-driven approaches, such as embedding techniques, have shown promise in improving survival predictions for advanced bladder cancer patients by leveraging datasets from various cancer types, including bladder cancer [21]. These methods emphasize the potential of integrating complex data modalities to enhance treatment precision.

Understanding complex signaling pathways within the tumor microenvironment—such as TGF-beta, PI3K/AKT/mTOR, MAPK, and Wnt—reveals their significant roles in cancer-associated fibroblasts (CAFs) and their interactions with cancer cells. These pathways are critical for CAF functions, including extracellular matrix remodeling, immune modulation, and promoting cancer cell proliferation and therapeutic resistance. This knowledge opens avenues for targeted interventions aimed at disrupting the crosstalk between CAFs and cancer cells, ultimately enhancing the effectiveness of cancer therapies [22, 11]. These pathways are pivotal in understanding the interaction between the tumor microenvironment and cancer progression, offering potential targets for novel therapeutic strategies.

3 Antibody-Drug Conjugates

Category	Feature	Method
Mechanism of Action and Components	Predictive Techniques	DBRNN[19]
Clinical Applications and Efficacy	Targeted Treatment Strategies	CF-HistoGAN[23], DCNN-LC[24]
Challenges and Limitations	Safety Concerns	ADCNet[25]

Table 1: Overview of Key Methods in Antibody-Drug Conjugate Research: This table categorizes and summarizes the principal methods employed in the study of antibody-drug conjugates (ADCs), focusing on their mechanisms of action, clinical applications, and associated challenges. The methods are organized into predictive techniques, targeted treatment strategies, and safety concerns, highlighting the diverse approaches used to enhance ADC design and efficacy in cancer therapy.

The development and application of antibody-drug conjugates (ADCs) represent a transformative approach in targeted cancer therapy, particularly in the context of advanced bladder cancer. This section delves into the intricate mechanisms underlying ADC functionality, focusing on their components and how these elements synergistically contribute to their therapeutic efficacy. Understanding the mechanisms of action is critical for optimizing ADC design and enhancing their clinical effectiveness. In this regard, we will first explore the mechanisms of action and the essential components that constitute ADCs, setting the foundation for a comprehensive discussion on their therapeutic potential and advancements in design. To aid in this exploration, **??** presents a hierarchical classification of key aspects in the development and application of ADCs in cancer therapy. This figure outlines the mechanisms, components, advancements in design, clinical applications, challenges, and future research directions associated with ADCs, highlighting their potential to enhance therapeutic efficacy and reduce systemic toxicity in targeted cancer treatments. Additionally, Table 2 offers a comprehensive summary of the methods used in the development and analysis of antibody-drug conjugates, categorizing them by their mechanisms, clinical applications, and challenges.

3.1 Mechanism of Action and Components

Antibody-drug conjugates (ADCs) are an innovative class of targeted therapeutics that aim to deliver cytotoxic agents directly to cancer cells, thereby minimizing systemic exposure and reducing off-target toxicity. The mechanism of action is based on the ability of monoclonal antibodies to specifically recognize and bind to antigens that are overexpressed on tumor cell surfaces [26]. Once bound, the ADCs are internalized by the cancer cells, leading to the release of the cytotoxic payload that induces cell death.

The efficacy of ADCs is reliant on the precise engineering of three fundamental components: the monoclonal antibody, the linker, and the cytotoxic payload. The monoclonal antibody component is

AI-generated, for reference only.

critical for the selective targeting of cancer cells, engineered to recognize specific tumor antigens, which ensures the specificity required for effective targeting [27]. The choice of antibody is crucial as it directly influences the ADC's binding affinity and therapeutic potential.

Linkers play a pivotal role in determining the stability and efficacy of ADCs, acting as the bridge between the antibody and the cytotoxic payload. They are categorized into cleavable and non-cleavable linkers, each with distinct mechanisms for drug release [28]. Cleavable linkers are designed to release the cytotoxic agent in response to specific intracellular conditions, such as enzymatic activity or acidic pH, ensuring that the payload is liberated after internalization. Non-cleavable linkers require the complete degradation of the antibody to release the cytotoxic agent, offering enhanced stability during circulation but necessitating efficient internalization [26].

The cytotoxic payload is the active component responsible for inducing cell death, typically a highly potent compound capable of killing cancer cells at low concentrations. The selection of an appropriate payload is crucial, as it must be effective against the targeted cancer cells while minimizing off-target effects [29]. The integration of these components into a single platform allows ADCs to deliver potent cytotoxic agents with precision, enhancing their therapeutic index and reducing collateral damage to healthy tissues.

Recent advancements in ADC technology have focused on improving the design of each component to enhance overall efficacy and safety. Efforts to refine the attachment methods of cytotoxic drugs to antibodies have been explored to ensure precise and controlled conjugation, optimizing the therapeutic profiles of ADCs [30]. Additionally, the application of deep learning approaches, such as Bayesian inference, provides robust predictive models that can enhance the precision of ADC development by offering uncertainty measures and improving decision-making in therapeutic design [19].

As illustrated in Figure 2, the key components and mechanisms of action of ADCs are highlighted, showcasing the roles of monoclonal antibodies, linkers, and cytotoxic payloads. This figure also emphasizes recent technological advancements in ADC design, conjugation methods, and predictive modeling for enhanced therapeutic efficacy. As research progresses, the continued refinement of ADC components promises to further enhance the clinical utility of this innovative therapeutic modality.



Figure 2: This figure illustrates the key components and mechanisms of action of antibody-drug conjugates (ADCs), highlighting the roles of monoclonal antibodies, linkers, and cytotoxic payloads. It also showcases recent technological advancements in ADC design, conjugation methods, and predictive modeling for enhanced therapeutic efficacy.

3.2 Advancements in ADC Design

Recent advancements in the design and development of antibody-drug conjugates (ADCs) have significantly enhanced their therapeutic potential, focusing on improving the specificity, efficacy, and safety of these targeted therapies. The evolution of ADCs can be categorized into three generations, each representing a step forward in antibody engineering, linker stability, and the potency of cytotoxic payloads [31]. First-generation ADCs laid the foundation by demonstrating the feasibility of this therapeutic approach, but they were limited by issues such as off-target toxicity and suboptimal therapeutic indices [30].

Second-generation ADCs introduced improvements in linker chemistry and drug conjugation techniques, addressing some of the limitations of their predecessors. These advancements were pivotal in enhancing the stability and controlled release of the cytotoxic payload, thereby reducing systemic toxicity [29]. The development of third-generation ADCs has focused on site-selective modification techniques, transitioning from heterogeneous to homogeneous ADCs, which has further refined their targeting capabilities and therapeutic efficacy [32].

The integration of organic and inorganic nanoparticles into ADC design has opened new avenues for enhancing drug delivery and therapeutic outcomes. Organic nanoparticles, such as liposomes and PLGA, offer advantages in biocompatibility and drug encapsulation, while inorganic nanoparticles, like gold and zinc oxide, provide unique properties for imaging and targeted delivery [33]. These innovations have expanded the versatility of ADCs, enabling more precise targeting and improved pharmacokinetics.

In addition to advancements in physical design, the integration of genomic, transcriptomic, and proteomic characterization of bladder cancer has been instrumental in guiding the development of ADCs, ensuring that these therapies are tailored to the molecular profiles of individual tumors [34]. This approach aligns with the broader trend in precision oncology, which seeks to leverage detailed molecular insights to enhance treatment efficacy and patient outcomes [5].

Despite these advancements, challenges remain in the complexity of ADC design, potential off-target effects, and the emergence of resistance mechanisms [35]. Innovative computational models, such as ADCNet, have been developed to predict ADC activity by merging protein and small molecule representation models, offering a unified framework that significantly advances the precision of ADC development [25]. As research continues to progress, these advancements promise to refine ADC technology further, enhancing its role as a cornerstone in the treatment of advanced bladder cancer.

3.3 Clinical Applications and Efficacy

Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic option in the treatment of advanced bladder cancer, offering a targeted approach that combines the specificity of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutic agents. The clinical application of ADCs in this context is primarily focused on their ability to selectively deliver cytotoxic payloads to cancer cells, thereby minimizing systemic toxicity and improving therapeutic outcomes [26]. The efficacy of ADCs in clinical settings is contingent upon the optimization of each component, including target selection, antibody type, linker stability, and payload potency, which are critical for achieving favorable clinical outcomes and reducing adverse effects [31].

Recent advancements in ADC technology have facilitated their integration into clinical practice, where they are utilized to target specific antigens overexpressed in bladder cancer cells. This targeted approach not only enhances the precision of drug delivery but also improves patient outcomes by reducing the collateral damage typically associated with conventional chemotherapy [2]. The integration of imaging techniques with ADC therapy has further enhanced clinical efficacy by allowing for real-time monitoring of treatment responses, providing a dynamic framework for assessing therapeutic effectiveness and adjusting treatment protocols as necessary [36].

The potential for ADCs to overcome resistance mechanisms in cancer therapy is another critical aspect of their clinical application. Research has identified multiple resistance pathways that can diminish the efficacy of traditional treatments, underscoring the need for novel ADCs and combination therapies that can enhance treatment efficacy [27]. By addressing these resistance mechanisms, ADCs offer a promising avenue for improving therapeutic outcomes in patients with advanced bladder cancer, particularly those who have exhausted other treatment options.

In addition to their therapeutic potential, ADCs also represent a cost-effective alternative to traditional treatment methods. The ability to accurately classify and target cancer cells using advanced imaging and classification techniques, such as those demonstrated in the classification of lymphocyte subtypes from Hoechst-stained images, highlights the potential for ADCs to streamline treatment processes and reduce overall healthcare costs [24]. As research continues to refine the components and application of ADCs, their role in the management of advanced bladder cancer is expected to expand, offering new hope for patients facing this challenging disease.

As shown in Figure 3, Antibody-drug conjugates (ADCs) represent a promising frontier in targeted cancer therapy, offering the potential for enhanced efficacy and reduced systemic toxicity. This innovative approach harnesses the specificity of monoclonal antibodies to deliver potent cytotoxic agents



(a) Generative Adversarial Network (GAN) Process for Image Generation[23]



(b) Comparison of PET/CT Images[36]

Figure 3: Examples of Clinical Applications and Efficacy

directly to cancer cells, minimizing damage to healthy tissues. The clinical applications and efficacy of ADCs can be illustrated through various examples, including advanced imaging techniques that aid in evaluating their therapeutic impact. For instance, the use of Generative Adversarial Networks (GANs) in image generation can enhance the visualization and analysis of treatment effects, offering insights into the nuanced changes in tumor biology. Additionally, comparative PET/CT imaging provides a detailed view of metabolic activity changes in response to ADC treatment, highlighting areas of increased uptake that may correlate with therapeutic efficacy. These technological advancements underscore the potential of ADCs in revolutionizing cancer treatment by providing precise and effective therapeutic options. [**?**]paulikat2023studyingtherapyeffectsdisease,bodei2022radiotheranostics)

3.4 Challenges and Limitations

The development and application of antibody-drug conjugates (ADCs) in the treatment of advanced bladder cancer are hindered by several significant challenges and limitations. A primary concern is the potential for systemic toxicity, which arises from the off-target effects of ADCs interacting with non-cancerous cells, thereby leading to adverse outcomes . This systemic toxicity is exacerbated by the heterogeneous nature of ADC products, which complicates the consistency and predictability of therapeutic effects [29].

Another critical challenge is the stability of the linker that connects the cytotoxic payload to the antibody. Premature release of the cytotoxic agent due to linker instability can result in reduced efficacy and increased toxicity, undermining the targeted delivery advantage of ADCs . Additionally, the large molecular size of ADCs can impede efficient tumor penetration, limiting their therapeutic potential in dense tumor environments [37].

Resistance mechanisms present a formidable obstacle in the clinical application of ADCs. These include antigen-related resistance, impaired internalization, dysfunctional lysosomal activity, and the overexpression of drug-efflux pumps, which collectively contribute to the reduced effectiveness of ADCs in targeting and killing cancer cells [27]. The adaptive nature of cancer cells, often leading to multidrug resistance, further complicates treatment regimens and necessitates the development of strategies to circumvent these resistance pathways [29].

The identification of suitable target antigens remains a challenge, as does the optimization of drug-antibody ratios (DAR), which is crucial for maintaining the balance between efficacy and toxicity [25]. The lack of adequate biomarkers for patient selection poses additional challenges, limiting the ability to tailor ADC therapies to individual patient profiles and thereby optimize therapeutic outcomes [26].

Despite these challenges, ongoing advancements in drug delivery systems and ADC technology hold promise for overcoming these limitations. The development of more stable linker technologies, improved methods for enhancing tumor penetration, and innovative approaches for predicting ADC activity are critical areas of focus that could enhance the clinical utility of ADCs [25]. Addressing these multifaceted challenges is essential for maximizing the therapeutic potential of ADCs in the treatment of advanced bladder cancer and improving patient outcomes.

3.5 Future Directions in ADC Research

The future of antibody-drug conjugate (ADC) research is poised for significant advancements, driven by the need to enhance therapeutic efficacy and expand the applicability of ADCs across diverse cancer types. A key area of focus is the refinement of site-selective modification techniques, which are crucial for improving the precision of ADCs and minimizing off-target effects [32]. The development of next-generation payloads, including novel classes that offer enhanced potency and specificity, is also a priority, as these innovations promise to improve the therapeutic index of ADCs.

As illustrated in Figure 4, the ongoing research into novel linker technologies is crucial for advancing ADCs, as optimizing linker stability and reactivity is essential for achieving controlled drug release. This optimization directly influences the therapeutic index, efficacy, and pharmacokinetics of ADCs, thereby enhancing their ability to deliver cytotoxic agents selectively to cancer cells while minimizing off-target effects. The figure highlights the primary future directions in ADC research, focusing on site-selective modifications, linker technologies, and overcoming resistance mechanisms. Each category underscores key advancements and strategies to enhance therapeutic efficacy and expand the applicability of ADCs in oncology. As ADCs continue to evolve, the development of more stable linkers and innovative release mechanisms remains a priority to improve treatment outcomes in oncology [38, 30, 26]. Innovations such as photo-sensitive, biorthogonal, and extracellular activation linkers are being investigated to enhance specificity and reduce systemic toxicity. These advancements in linker technology are complemented by the pursuit of bispecific ADCs and the integration of molecular imaging techniques, which collectively aim to enhance targeting accuracy and therapeutic outcomes.

Overcoming resistance mechanisms is another pivotal focus in ADC research. Strategies such as combination therapies with immunotherapies are being explored to mitigate resistance and improve patient responses. The identification of better predictive biomarkers is essential for tailoring ADC therapies to individual patient profiles, thereby maximizing clinical benefits and expanding the application of ADCs in oncology [26].

Furthermore, expanding the applications of ADCs beyond cancer treatment is an emerging trend, with research exploring their potential in other disease contexts [39]. Addressing the cost-effectiveness of ADC therapies is crucial to making them more accessible, necessitating innovative conjugation techniques and scalable production methods [29].



Figure 4: This figure illustrates the primary future directions in Antibody-Drug Conjugate (ADC) research, focusing on site-selective modifications, linker technologies, and overcoming resistance mechanisms. Each category highlights key advancements and strategies to enhance therapeutic efficacy and expand the applicability of ADCs in oncology.

4 Immunotherapy

Immunotherapy has fundamentally transformed oncology by harnessing the immune system to combat cancer. This section delves into the mechanisms of immunotherapy, focusing on immune checkpoint pathways, tumor microenvironment interactions, and innovative strategies that enhance immune responses against tumors. Understanding these mechanisms is vital for recognizing immunotherapy's therapeutic potential and limitations, particularly in advanced cancer contexts.

Feature	Mechanism of Action and Components	Advancements in ADC Design	Clinical Applications and Efficacy
Mechanism of Action	Targeted Cell Death	Improved Targeting	Selective Delivery
Component Design	Antibody, Linker, Payload	Enhanced Stability	Optimized Components
Clinical Applications	Cancer Targeting	Bladder Cancer	Advanced Cancer

Table 2: The table provides a detailed comparison of key features in the development of antibody-drug conjugates (ADCs), highlighting the mechanisms of action, component design, and clinical applications. It outlines the advancements in ADC design, such as improved targeting and stability, and their efficacy in cancer therapy, particularly in bladder and advanced cancers. This comprehensive overview underscores the potential of ADCs to enhance therapeutic efficacy and reduce systemic toxicity in targeted cancer treatments.

4.1 Mechanisms of Immunotherapy

Immunotherapy targets cancer cells by modulating immune checkpoint pathways like PD-1/PD-L1 and CTLA-4, which tumors exploit to evade immune detection. Immune checkpoint inhibitors (ICIs) reinvigorate T-cell activity, enhancing anti-tumor responses, though challenges in delivering these therapies to solid tumors often limit efficacy and can cause severe side effects [40]. Biomathematical models, such as spatially explicit stochastic individual-based models, offer insights into CD8+ T cells and tumor cell dynamics, elucidating the impact of intra-tumor heterogeneity (ITH) on immune responses [41, 20].

CAR T-cell therapy exemplifies an innovative approach, where T cells are engineered to express chimeric antigen receptors targeting tumor antigens, promoting robust immune attacks. Advanced protein engineering addresses challenges like glycosylation, optimizing CAR design for enhanced safety and efficacy [42]. Cytokines, such as IL-2 and IFN, modulate immune responses, with ongoing research exploring their use in combination therapies to enhance outcomes and overcome resistance [43, 44]. Innovations in delivery technologies aim to localize cytokine concentrations at tumor sites, maximizing immunomodulatory effects while minimizing adverse reactions [40].



(a) Immune Escape from Tumor Cells[45]



(b) Interactions between T-cells and tumor cells.[46]

Figure 5: Examples of Mechanisms of Immunotherapy

As shown in Figure 5, immunotherapy employs the immune system to target tumor cells. The first image illustrates the immune escape phenomenon, where tumors evade detection by immune cells, while the second image highlights T-cell and tumor cell interactions, emphasizing T-cell receptors in immune signaling [45, 46].

4.2 Effectiveness and Limitations

Immunotherapy, particularly ICIs like pembrolizumab and atezolizumab, has provided significant survival benefits in advanced bladder cancer, especially for patients with high PD-L1 expression [40]. By disrupting pathways such as PD-1/PD-L1, these agents restore immune surveillance and enhance T-cell-mediated anti-tumor activity. However, the efficacy of ICIs as monotherapy is often limited, necessitating combination therapies that target multiple pathways within the cancer-immunity cycle to strengthen immune responses.

The immunosuppressive tumor microenvironment (TME) complicates immunotherapy delivery and can induce autoimmune reactions, hindering treatment outcomes [40]. Additionally, ITH complicates efficacy, as tumors with diverse sub-populations exhibit diminished immune responses [20]. Understanding ITH is crucial for optimizing therapeutic strategies and predicting treatment outcomes.

Combination therapies with ICIs have shown promise in enhancing response rates and survival across cancers by addressing multiple resistance mechanisms, including TME and intrinsic cancer cell resistance. However, the complexity of immune interactions and variability in patient responses necessitate personalized approaches to optimize treatment regimens [41]. Despite advancements, challenges like unpredictable efficacy and resistance development remain, highlighting the need for additional biomarkers to guide therapy decisions and innovative trial methodologies [40].

4.3 Innovative Approaches and Models

Innovative approaches in immunotherapy for advanced bladder cancer emphasize multi-modal strategies that combine immunotherapy with other modalities to overcome TME limitations [40]. These combination therapies exploit synergistic effects, enhancing immune responses and improving outcomes, as evidenced by advancements in various cancer types [43].

Advanced computational models are essential for understanding tumor-immune dynamics, providing insights into TME interactions. Humanized mouse models have elucidated tumor-immune interactions and tested various immunotherapeutic strategies, demonstrating their utility in preclinical studies [47]. These models facilitate exploration of immune mechanisms and rational combinations, critical for optimizing immunotherapy strategies.

Predictive models for immunotherapy outcomes, such as deep learning-based approaches, are being explored to predict tumor mutational burden (TMB) status from routine histopathological slides, enhancing treatment predictions and supporting broader applications in low-resource settings [40]. Future research should focus on new immunotherapy combinations, understanding resistance mechanisms, and expanding indications for existing treatments [48].

Innovative clinical trial designs, like adaptive trials, facilitate real-time decision-making based on available data, addressing challenges posed by delayed responses and enhancing immunotherapy efficacy evaluation. These approaches underscore the potential of leveraging diverse data modalities to improve the precision and effectiveness of immunotherapy [40]. These innovative approaches and models signify substantial advancements in immunotherapy for advanced bladder cancer, offering new pathways for treatment optimization and improved patient outcomes. As research progresses, advancements in drug delivery systems, combination therapies, and antiangiogenic agents aim to enhance efficacy and broaden access, addressing challenges like immune modulation, treatment resistance, and biomarker identification [6, 43, 40, 49, 4].

5 Targeted Therapy

Targeted therapy for advanced bladder cancer demands a thorough understanding of molecular mechanisms and identification of specific therapeutic targets. This section explores molecular target identification and genomic analysis, essential for developing effective therapies. By elucidating the molecular landscape of bladder cancer, researchers can pinpoint key oncogenic drivers, enabling personalized interventions aligned with individual tumor characteristics. The following subsection details methodologies for molecular target identification and the implications of genomic analysis in advancing targeted therapeutic strategies.

5.1 Molecular Target Identification and Genomic Analysis

Molecular target identification and genomic analysis are pivotal in developing targeted therapies for advanced bladder cancer. Advances in next-generation sequencing have revealed driver mutations and actionable targets, enhancing our understanding of patient prognosis and therapeutic strategies, while informing the cellular landscape of bladder tumors with diverse cell populations. These insights are crucial for predicting therapeutic responses and improving treatment outcomes, especially with emerging non-invasive diagnostic methods like liquid biopsies and immune checkpoint inhibitors [34, 5]. The process begins with characterizing the tumor's molecular landscape, integrating genomic, transcriptomic, and proteomic data to identify key oncogenic drivers. High-throughput sequencing technologies have improved our ability to profile tumors at the molecular level, facilitating the identification of genetic alterations and pathways driving cancer progression.

Genomic analysis has uncovered various molecular alterations in bladder cancer, including mutations in FGFR3, TP53, and PIK3CA, and alterations in pathways like RTK/RAS/PI3K. These discoveries have propelled the development of targeted therapies aimed at inhibiting critical signaling pathways involved in cancer progression, particularly by addressing dysregulated mechanisms such as growth factors and cell death pathways. This approach seeks not only to halt tumor growth but also to provide individualized treatment options based on unique genetic profiles, enhancing therapy efficacy and addressing challenges related to treatment resistance and tumor heterogeneity [3, 1, 11]. Identifying actionable mutations through genomic profiling is essential for precision medicine, allowing for targeted therapies tailored to individual molecular profiles.

Despite advancements, determining optimal doses for targeted oncology drugs remains challenging. Traditional dose escalation methods, which focus on maximum tolerated doses, often fail to optimize therapeutic efficacy and safety. Innovative approaches like the DroidDose ranging strategy are being explored to optimize dosing based on a comprehensive understanding of drug pharmacodynamics and pharmacokinetics [50]. These strategies aim to maximize the therapeutic window of targeted therapies, ensuring patients receive the most effective and safe treatment possible.

5.2 Personalized Treatment Strategies

Personalized treatment strategies in advanced bladder cancer leverage targeted therapy to enhance outcomes by tailoring interventions to individual molecular and clinical profiles. This approach relies on identifying genetic alterations and molecular pathways driving tumor progression, facilitating targeted therapies aligned with biological characteristics. Advances in precision oncology, including genomic profiling and multimodal data integration, address tumor heterogeneity and improve treatment efficacy. Consequently, therapies can be optimized based on variations in tumor genetics, drug sensitivity, and resistance mechanisms, leading to more effective cancer care [10, 51, 11]. Integrating genomic profiling into clinical practice allows for identifying actionable mutations and selecting effective targeted therapies.

Optimizing dosing regimens is critical to maximize efficacy while minimizing toxicity. Traditional dose escalation methods often fall short, prompting exploration of innovative approaches like the DROID (Dose Ranging Optimization in Drug development) model. This two-stage design identifies the therapeutic dose range and assesses the dose-response relationship, facilitating optimal dose selection in oncology trials [50]. By refining dose selection, DROID aims to enhance the therapeutic window of targeted therapies, ensuring effective and safe treatment.

Incorporating socio-demographic parameters significantly influences treatment responses. Mathematical modeling approaches integrating these parameters are being developed to enhance personalization of therapies like Bacillus Calmette-Guérin (BCG) for bladder cancer [52]. These models provide a comprehensive understanding of factors impacting efficacy, enabling clinicians to tailor interventions more precisely.

Personalized treatment strategies represent a transformative advancement in managing advanced bladder cancer, leveraging insights from next-generation sequencing and genomic profiling to tailor interventions to each patient's distinct characteristics. This approach enhances identification of actionable targets and prognostic indicators, while improving monitoring capabilities through non-invasive methods like liquid biopsies. Integrating immune checkpoint inhibitors has shown promise in significantly improving outcomes, offering hope for extended survival and better quality of life [12, 5]. As research progresses, integrating genomic insights, innovative dosing approaches, and socio-demographic considerations promises to further refine these strategies and expand their impact in oncology.

5.3 Optimization of Targeted Therapy Dosing

Optimizing dosing of targeted therapies in advanced bladder cancer is essential for maximizing efficacy while minimizing adverse effects. Traditional strategies focusing on maximum tolerated dose may not adequately address complex interactions between pharmacological agents and the tumor

AI-generated, for reference only.

microenvironment, leading to suboptimal outcomes, particularly concerning drug resistance and tumor heterogeneity. Recent advancements, such as the FDA's Project Optimus and the Dose-ranging Approach to Optimizing Dose (DROID), emphasize nuanced dose optimization considering both efficacy and toxicity profiles. Additionally, combination cancer therapies (CCTs) are increasingly employed to tackle molecular and pathophysiological challenges, presenting a promising avenue for enhancing survival rates. Integrating mathematical modeling and innovative delivery technologies, like nanoparticles for immunotherapy, could further refine strategies and improve responses while minimizing adverse effects [8, 40, 50]. Innovative approaches leverage real-time data and mathematical modeling to refine dosing regimens.

Optimal control strategies facilitate dynamic adjustment of treatment plans based on ongoing interactions between therapies and biological responses. This method provides a framework for continuously optimizing dosing to enhance treatment efficacy and outcomes [16]. By integrating mathematical models simulating pharmacokinetics and pharmacodynamics, clinicians can tailor dosing regimens responsive to the evolving clinical picture, improving the therapeutic index.

Machine learning algorithms and sophisticated computational tools significantly enhance dosing optimization by enabling analysis of multimodal data, including molecular diagnostics, imaging, and clinical data, to identify optimal therapeutic dose ranges balancing efficacy and safety. This approach addresses challenges posed by sparse datasets and complex biological systems, facilitating creation of personalized treatment strategies through enhanced predictive modeling and data-driven insights [23, 50, 53, 10]. These technologies enable analysis of large datasets to predict patient-specific responses to therapies, supporting identification of optimal dosing strategies personalized to individual profiles, reducing toxicity risk and improving treatment success.

Adaptive dosing protocols involve real-time monitoring of biomarkers and responses, allowing for dosing adjustments in response to changes in tumor dynamics and condition. Implementing adaptive protocols prioritizes flexibility and patient-centered care, reducing side effects while ensuring desired therapeutic efficacy. This approach is crucial in precision oncology, where tumor heterogeneity necessitates individualized strategies based on genomic profiling. Initiatives like the FDA's Project Optimus underscore the shift away from traditional "more is better" paradigms, advocating for dose optimization strategies considering both efficacy and safety. This framework includes methods like the DROID, integrating established dose-ranging study designs to identify optimal therapeutic dose ranges balancing acceptable toxicity with effective outcomes [50, 54, 11].

6 Oncology Research and Future Directions

6.1 Integration of Data Modalities in Research

Integrating diverse data modalities in oncology research enhances treatment strategies and patient outcomes by combining histopathology, radiology, genomics, and clinical data. This comprehensive approach reveals intricate cancer biology and progression patterns, often missed when modalities are isolated [21]. Stochastic individual-based models capture tumor heterogeneity and cell interactions, providing insights into tumor-immune dynamics essential for developing effective therapies [55]. Adaptive Bayesian clinical trial designs improve patient allocation and subpopulation identification, facilitating real-time integration of diverse data modalities and expediting research findings into clinical practice [56]. Machine learning techniques, particularly embedding-based relational learning frameworks, enhance clinical outcome predictions from multimodal datasets, optimizing treatment plans [21]. Clinical data integration with interim analyses in seamless phase 2-3 trial designs exemplifies modern research's adaptability, allowing optimal dose selection based on benefit-risk tradeoffs [57].

6.2 Innovative Trial Designs and Efficacy Assessment

Innovative trial designs are vital for assessing new oncology treatments, especially for complex diseases like advanced bladder cancer. These designs incorporate adaptive methodologies that enhance trial precision, enabling accurate treatment efficacy assessments. Randomization and predictive probability monitoring facilitate early stopping for futility and reliable therapeutic evaluations [57]. Adaptive Bayesian designs improve patient allocation and subpopulation identification, optimizing benefit-risk balance through dynamic adjustments [56]. Trial performance is validated by comparing

Benchmark	Size	Domain	Task Format	Metric
ClinTaT[58]	1,479	Cancer Prognosis	Binary Classification	AUC, C-index
RMST[59]	330	Oncology	Survival Analysis	Power, RMST
max-BEP[18]	361	Oncology	Survival Analysis	Bayesian Expected Power, Type I error rate

Table 3: This table presents a selection of representative benchmarks used in the evaluation of innovative trial designs for oncology treatments. It details the size, domain, task format, and metrics employed for each benchmark, providing a comprehensive overview of their application in cancer prognosis and survival analysis contexts.

estimated survival curves and Net Monetary Benefit to known synthetic datasets, enhancing reliability [60]. Frequentist and Bayesian models, such as Cox and Weibull AFT models, provide a comprehensive framework for understanding therapeutic efficacy [61]. Table 3 illustrates the benchmarks utilized to validate the performance of innovative trial designs, highlighting their relevance in oncology treatment efficacy assessments.

6.3 Mathematical Modeling and Combination Therapies

Mathematical modeling integrated with combination therapies advances treatment for complex diseases like advanced bladder cancer. These models offer robust frameworks for understanding tumor-immune interactions, optimizing therapeutic strategies. Delay differential equations model immune responses to tumors, providing nuanced insights into immune-tumor dynamics [62]. Dynamical systems models describing PD-1 and PD-L1 interactions elucidate immune checkpoint pathways' interplay with tumor cells, simulating immune evasion mechanisms and checkpoint inhibitors' impacts [46]. Optimal control theory refines combination therapy strategies by modeling tumor-immune cell interactions, enabling real-time dosing regimen optimization [16]. The DROID approach exemplifies adaptive modeling, allowing real-time adjustments to optimize safety and efficacy in combination therapies [50].

6.4 Innovative Therapeutic Strategies

Innovative therapeutic strategies in oncology integrate advanced technologies and combinatory approaches to enhance efficacy and minimize adverse effects. Coupled impulsive delay differential equations offer precise modeling of biological delays and interactions, facilitating therapeutic optimization [41]. The PARADIGM method, utilizing graph neural networks, leverages complex interrelations among cancer-related variables, enhancing therapeutic precision by integrating diverse data sources [21]. Exploring intra-tumor heterogeneity through mathematical modeling provides insights into immune response variability, informing effective therapeutic strategies [20]. Bayesian Neural Networks enhance predictive model robustness by providing confidence metrics alongside performance predictions, supporting informed treatment decisions [19].

6.5 Combination Therapy Approaches

Combination therapy in advanced bladder cancer enhances therapeutic efficacy by leveraging multiple modalities' synergistic effects. Combining immune checkpoint inhibitors with chemotherapy and other agents is under investigation, optimizing these combinations for improved outcomes [14]. Studies show enhanced efficacy when antiangiogenic therapies are combined with ICIs, disrupting the tumor microenvironment and enhancing immune activity [6]. Challenges include integrating multimodal data, developing robust models to predict efficacy, and addressing ethical and logistical clinical trial hurdles [8, 10]. Future research should refine seamless phase 2-3 designs, incorporating adaptive strategies and endpoints to understand combination therapy dynamics better [54].

6.6 Technological Innovations in Oncology

Technological innovations transform oncology research and treatment, enhancing precision, efficacy, and patient outcomes. AI and ML techniques improve complex dataset analysis, identifying novel biomarkers and therapeutic targets for personalized treatment strategies [21]. Graph neural networks, exemplified by PARADIGM, capture intricate patterns in graph-structured data, enhancing therapeutic precision through diverse modality integration [21]. Advanced imaging technologies, like radiotheranostics, combine diagnostic imaging with targeted radiotherapy, enhancing tumor localization and treatment delivery [36]. Mathematical modeling and simulations offer frameworks for understanding tumor-immune dynamics and optimizing therapies [16]. Novel drug delivery systems, such as nanoparticle-based platforms, improve targeted therapy precision, expanding the therapeutic window and offering hope for improved outcomes [33].

6.7 Future Research Directions

Future research in advanced bladder cancer treatment will advance through innovative methodologies and comprehensive data analyses. Refining the PARADIGM framework to adapt to new cancer types and explore additional data modalities will improve therapeutic precision [21]. Developing next-generation ADCs and combination therapies integrating immune checkpoint inhibitors with ADCs will enhance specificity and efficacy [27]. Advancing delivery systems targeting the tumor microenvironment will improve immune cell infiltration and immunotherapy efficacy [40]. Refining Optimal Efficiency Predictive Probability Designs will facilitate accurate therapeutic assessments across diverse cancer contexts [57]. Future ADC research should focus on novel warheads, improved linkers, and better tumor biology understanding [30]. Enhancing predictive capabilities through diverse dataset integration will refine ADC therapy precision [25]. Mathematical modeling will remain pivotal, integrating biological factors and clinical data to offer tailored interventions [20]. Optimizing Bayesian methods' computational efficiency and exploring clinical applications will advance oncology decision-making processes [19].

7 Conclusion

Advanced bladder cancer treatment strategies underscore a critical need for continued research and innovation within oncology. Recent developments, including antibody-drug conjugates, immunotherapy, and targeted therapies, offer promising avenues by employing distinct mechanisms to combat this formidable disease. Understanding molecular subtypes and variant histology is integral to fostering personalized therapy, highlighting the significance of precision oncology.

The integration of multimodal data enriches our comprehension of cancer biology, facilitating the discovery of novel biomarkers and significantly advancing precision oncology to enhance patient outcomes. This comprehensive approach is crucial for devising personalized treatment strategies that address the multifaceted challenges of advanced bladder cancer.

Moreover, the importance of social awareness in managing risk factors and the implementation of high-quality surgical techniques are emphasized as pivotal components of effective cancer management. As the field progresses, these advancements hold considerable promise for improving survival rates and quality of life for patients with advanced bladder cancer. Ongoing commitment to research and innovation is essential to navigate the complexities of this disease and propel cancer treatment forward.

References

[1] Fu Peng, Minru Liao, Rui Qin, Shiou Zhu, Cheng Peng, Leilei Fu, Yi Chen, and Bo Han. Regulated cell death (rcd) in cancer: key pathways and targeted therapies. *Signal transduction and targeted therapy*, 7(1):286, 2022.

[2] Michael J Mitchell, Rakesh K Jain, and Robert Langer. Engineering and physical sciences in oncology: challenges and opportunities. *Nature Reviews Cancer*, 17(11):659–675, 2017.

[3] Narges Ramezani and Erfan Mohammadi. The role of public health in the fight against cancer: Awareness, prevention, and early detection, 2023.

[4] C Lee Ventola. Cancer immunotherapy, part 3: challenges and future trends. *Pharmacy and Therapeutics*, 42(8):514, 2017.

[5] Linda Tran, Jin-Fen Xiao, Neeraj Agarwal, Jason E Duex, and Dan Theodorescu. Advances in bladder cancer biology and therapy. *Nature Reviews Cancer*, 21(2):104–121, 2021.

[6] Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar, Dan G Duda, and Rakesh K Jain. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. *Nature reviews Clinical oncology*, 15(5):325–340, 2018.

[7] Mazen Alamir. Learning-based sensitivity analysis and feedback design for drug delivery of mixed therapy of cancer in the presence of high model uncertainties, 2022.

[8] Joseph Malinzi, Kevin Bosire Basita, Sara Padidar, and Henry A. Adeola. Prospect for application of mathematical models in combination cancer treatments, 2021.

[9] Subhadip Raychaudhuri. Low probability bid-bax reaction generates heterogeneity in apoptosis resistance of cancer and cancer stem cells, 2011.

[10] Kevin M Boehm, Pegah Khosravi, Rami Vanguri, Jianjiong Gao, and Sohrab P Shah. Harnessing multimodal data integration to advance precision oncology. *Nature Reviews Cancer*, 22(2):114–126, 2022.

[11] Manish Kumar. Precision oncology, signaling pathways reprogramming and targeted therapy: A holistic approach to molecular cancer therapeutics, 2024.

[12] Tania Processali, Alberto Diminutto, Maria Angela Cerruto, and Alessandro Antonelli. The impact of histological variants on bladder cancer outcomes. *AME Med J*, 5(4), 2020.

[13] Oner Sanli, Jakub Dobruch, Margaret A Knowles, Maximilian Burger, Mehrdad Alemozaffar, Matthew E Nielsen, and Yair Lotan. Bladder cancer. *Nature reviews Disease primers*, 3(1):1–19, 2017.

[14] Antonio Lopez-Beltran, Alessia Cimadamore, Ana Blanca, Francesco Massari, Nuno Vau, Marina Scarpelli, Liang Cheng, and Rodolfo Montironi. Immune checkpoint inhibitors for the treatment of bladder cancer. *Cancers*, 13(1):131, 2021.

[15] Jakub Dobruch and Maciej Oszczudłowski. Bladder cancer: current challenges and future directions. *Medicina*, 57(8):749, 2021.

[16] Jayanth Pratap. An optimal control strategy for mathematically modeling cancer combination therapy, 2021.

[17] Michel Fliess, Cédric Join, Kaouther Moussa, Seddik M. Djouadi, and Mohamed W. Alsager. Toward simple "in silico" experiments for drugs administration in some cancer treatments, 2021.

[18] Andrea Arfé, Brian Alexander, and Lorenzo Trippa. Optimality of testing procedures for survival data, 2020.

[19] Geoffroy Dubourg-Felonneau, Omar Darwish, Christopher Parsons, Dami Rebergen, John W Cassidy, Nirmesh Patel, and Harry W Clifford. Safety and robustness in decision making: Deep bayesian recurrent neural networks for somatic variant calling in cancer, 2019.

[20] Emma Leschiera, Tommaso Lorenzi, Shensi Shen, Luis Almeida, and Chloe Audebert. A mathematical model to study the impact of intra-tumour heterogeneity on anti-tumour cd8+ t cell immune response, 2021.

[21] Asim Waqas, Aakash Tripathi, Paul Stewart, Mia Naeini, Matthew B Schabath, and Ghulam Rasool. Embedding-based multimodal learning on pan-squamous cell carcinomas for improved survival outcomes. *arXiv preprint arXiv:2406.08521*, 2024.

[22] Fanglong Wu, Jin Yang, Junjiang Liu, Ye Wang, Jingtian Mu, Qingxiang Zeng, Shuzhi Deng, and Hongmei Zhou. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. *Signal transduction and targeted therapy*, 6(1):218, 2021.

[23] Martin Paulikat, Christian M. Schürch, and Christian F. Baumgartner. Studying therapy effects and disease outcomes in silico using artificial counterfactual tissue samples, 2023.

[24] Jessica Cooper, In Hwa Um, Ognjen Arandjelović, and David J Harrison. Hoechst is all you need: Lymphocyte classification with deep learning, 2021.

[25] Liye Chen, Biaoshun Li, Yihao Chen, Mujie Lin, Shipeng Zhang, Chenxin Li, Yu Pang, and Ling Wang. Adcnet: a unified framework for predicting the activity of antibody-drug conjugates, 2024.

[26] Joshua Z Drago, Shanu Modi, and Sarat Chandarlapaty. Unlocking the potential of antibody–drug conjugates for cancer therapy. *Nature Reviews Clinical Oncology*, 18(6):327–344, 2021.

[27] Rita Khoury, Khalil Saleh, Nadine Khalife, Mohamad Saleh, Claude Chahine, Rebecca Ibrahim, and Axel Lecesne. Mechanisms of resistance to antibody-drug conjugates. *International journal of molecular sciences*, 24(11):9674, 2023.

[28] Anna Wolska-Washer and Tadeusz Robak. Safety and tolerability of antibody-drug conjugates in cancer. *Drug safety*, 42(2):295–314, 2019.

[29] Nirnoy Dan, Saini Setua, Vivek K Kashyap, Sheema Khan, Meena Jaggi, Murali M Yallapu, and Subhash C Chauhan. Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. *Pharmaceuticals*, 11(2):32, 2018.

[30] Alain Beck, Liliane Goetsch, Charles Dumontet, and Nathalie Corvaïa. Strategies and challenges for the next generation of antibody–drug conjugates. *Nature reviews Drug discovery*, 16(5):315–337, 2017.

[31] Zhiwen Fu, Shijun Li, Sifei Han, Chen Shi, and Yu Zhang. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. *Signal transduction and targeted therapy*, 7(1):93, 2022.

[32] Stephen J Walsh, Jonathan D Bargh, Friederike M Dannheim, Abigail R Hanby, Hikaru Seki, Andrew J Counsell, Xiaoxu Ou, Elaine Fowler, Nicola Ashman, Yuri Takada, et al. Site-selective modification strategies in antibody–drug conjugates. *Chemical Society Reviews*, 50(2):1305–1353, 2021.

[33] Huailan Wang, Yunxiang Zhou, Qunan Sun, Chenghao Zhou, Shiyao Hu, Cameron Lenahan, Weilin Xu, Yongchuan Deng, Gonghui Li, and Sifeng Tao. Update on nanoparticle-based drug delivery system for anti-inflammatory treatment. *Frontiers in Bioengineering and Biotechnology*, 9:630352, 2021.

[34] Constantine Alifrangis, Ursula McGovern, Alex Freeman, Thomas Powles, and Mark Linch. Molecular and histopathology directed therapy for advanced bladder cancer. *Nature Reviews Urology*, 16(8):465–483, 2019.

[35] Umbreen Hafeez, Sagun Parakh, Hui K Gan, and Andrew M Scott. Antibody–drug conjugates for cancer therapy. *Molecules*, 25(20):4764, 2020.

[36] Lisa Bodei, Ken Herrmann, Heiko Schöder, Andrew M Scott, and Jason S Lewis. Radiotheranostics in oncology: current challenges and emerging opportunities. *Nature Reviews Clinical Oncology*, 19(8):534–550, 2022.

[37] Nicola Ashman, Jonathan D Bargh, and David R Spring. Non-internalising antibody–drug conjugates. *Chemical Society Reviews*, 51(22):9182–9202, 2022.

[38] Rotimi Sheyi, Beatriz G de la Torre, and Fernando Albericio. Linkers: an assurance for controlled delivery of antibody-drug conjugate. *Pharmaceutics*, 14(2):396, 2022.

[39] Stephanie Baah, Mark Laws, and Khondaker Miraz Rahman. Antibody–drug conjugates—a tutorial review. *Molecules*, 26(10):2943, 2021.

[40] Rachel S Riley, Carl H June, Robert Langer, and Michael J Mitchell. Delivery technologies for cancer immunotherapy. *Nature reviews Drug discovery*, 18(3):175–196, 2019.

[41] Isabel González-Crespo, Antonio Gómez-Caamaño, Óscar López Pouso, John D. Fenwick, and Juan Pardo-Montero. A biomathematical model of tumor response to radioimmunotherapy with αpdl1 and αctla4, 2022.

[42] Matthew J Buettner, Sagar R Shah, Christopher T Saeui, Ryan Ariss, and Kevin J Yarema. Improving immunotherapy through glycodesign. *Frontiers in immunology*, 9:2485, 2018.

[43] Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li, and Chong-xian Pan. Combination strategies to maximize the benefits of cancer immunotherapy. *Journal of hematology & oncology*, 14(1):156, 2021.

[44] Thomas A Waldmann. Cytokines in cancer immunotherapy. *Cold Spring Harbor perspectives in biology*, 10(12):a028472, 2018.

[45] Paul L Crispen and Sergei Kusmartsev. Mechanisms of immune evasion in bladder cancer. *Cancer Immunology, Immunotherapy*, 69(1):3–14, 2020.

[46] Kamran Kaveh and Feng Fu. Immune checkpoint therapy modeling of pd-1/pd-l1 blockades reveals subtle difference in their response dynamics and potential synergy in combination, 2021.

[47] Jane Chuprin, Hannah Buettner, Mina O Seedhom, Dale L Greiner, James G Keck, Fumihiko Ishikawa, Leonard D Shultz, and Michael A Brehm. Humanized mouse models for immuno-oncology research. *Nature Reviews Clinical Oncology*, 20(3):192–206, 2023.

[48] Jessica Eno. Immunotherapy through the years. *Journal of the advanced practitioner in oncology*, 8(7):747, 2017.

[49] Timothy A Yap, Eileen E Parkes, Weiyi Peng, Justin T Moyers, Michael A Curran, and Hussein A Tawbi. Development of immunotherapy combination strategies in cancer. *Cancer discovery*, 11(6):1368–1397, 2021.

[50] Beibei Guo and Ying Yuan. Droid: Dose-ranging approach to optimizing dose in oncology drug development, 2022.

[51] Heather D. Couture. Deep learning-based prediction of molecular tumor biomarkers from he: A practical review, 2022.

[52] Elizaveta Savchenko, Ariel Rosenfeld, and Svetlana Bunimovich-Mendrazitsky. Mathematical modeling of bcg-based bladder cancer treatment using socio-demographics, 2023.

[53] Katarzyna Janocha, Annabel Ling, Alice Godson, Yulia Lampi, Simon Bornschein, and Nils Y. Hammerla. Harnessing preference optimisation in protein lms for hit maturation in cell therapy, 2024.

[54] Liyun Jiang and Ying Yuan. Seamless phase 2-3 design: A useful strategy to reduce the sample size for dose optimization, 2022.

[55] Martina Baar, Loren Coquille, Hannah Mayer, Michael Hölzel, Meri Rogava, Thomas Tüting, and Anton Bovier. A stochastic individual-based model for immunotherapy of cancer, 2016.

[56] Yanxun Xu, Peter Mueller, Apostolia M Tsimberidou, and Donald Berry. A nonparametric bayesian basket trial design, 2018.

[57] Emily C. Zabor, Alexander M. Kaizer, Nathan A. Pennell, and Brian P. Hobbs. Optimal predictive probability designs for randomized biomarker-guided oncology trials, 2022.

[58] Zekai Chen, Mariann Micsinai Balan, and Kevin Brown. Language models are few-shot learners for prognostic prediction, 2023.

[59] José L. Jiménez. Quantifying treatment differences in confirmatory trials under non-proportional hazards, 2020.

[60] Elizabeth A. Handorf, J. Robert Beck, and Daniel M. Geynisman. Modeling therapy sequence for advanced cancer: A microsimulation approach leveraging electronic health record data, 2024.

[61] Guanbo Wang, Melanie Poulin Costello, Herbert Pang, Jiawen Zhu, Hans-Joachim Helms, Irmarie Reyes-Rivera, Robert W. Platt, Menglan Pang, and Artemis Koukounari. Evaluating hybrid controls methodology in early-phase oncology trials: a simulation study based on the morpheus-uc trial, 2023.

[62] D. Rodriguez-Perez, Oscar Sotolongo-Grau, Ramon Espinosa Riquelme, Oscar Sotolongo-Costa, J. Antonio Santos Miranda, and J. C. Antoranz. Tumors under periodic therapy – role of the immune response time delay, 2006.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.